

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – April 10, 2024 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Bret Haymore –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person
Dr. Cindy West –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_R_AmCBepQpGQggKXT40uxg

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 919 6475 4191

Passcode: 95646190

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. March 13, 2024 DUR Board Meeting Minutes
- B. March 13, 2024 DUR Board Recommendations Memorandum

Items to be presented by Dr. Moss, Dr. Travers, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/SoonerPsych and Pediatric SoonerPsych Antipsychotic Monitoring Program Update – See Appendix B

- A. Pharmacy Help Desk Activity for March 2024
- B. Medication Coverage Activity for March 2024
- C. SoonerPsych and Pediatric SoonerPsych Antipsychotic Monitoring Program Update

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Roctavian™ (Valoctocogene Roxaparvovec-rvox) – See Appendix C

- A. Market News and Updates
- B. Roctavian™ (Valoctocogene Roxaparvovec-rvox) Product Summary
- C. OHCA Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Ngenla™ (Somatrogon-ghla) and Update the Approval Criteria for the Growth Hormone Products and Voxzogo® (Vosoritide) – See Appendix D

- A. Market News and Updates
- B. Ngenla™ (Somatrogon-ghla) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Ryzneuta® (Efbemalenogastim Alfa) and Update the Approval Criteria for the Granulocyte Colony-Stimulating Factors (G-CSFs) – See Appendix E

- A. Market News and Updates
- B. Ryzneuta® (Efbemalenogastim Alfa) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Tyruko® (Natalizumab-sztn) and Update the Approval Criteria for the Multiple Sclerosis (MS) Medications – See Appendix F

- A. Market News and Updates
- B. Tyruko® (Natalizumab-sztn) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Aphexda™ (Motixafortide) and Update the Approval Criteria for the Stem Cell Mobilizers – See Appendix G

- A. Market News and Updates
- B. Aphexda™ (Motixafortide) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

10. Vote to Prior Authorize Columvi™ (Glofitamab-gxbm) and Epkinly™ (Epcoritamab-bysp) and Update the Approval Criteria for the Lymphoma Medications – See Appendix H

- A. Market News and Update
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

11. Action Item – Annual Review of Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of ADHD and Narcolepsy Medications
- C. Prior Authorization of ADHD and Narcolepsy Medications

- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of ADHD and Narcolepsy Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

12. Action Item – Annual Review of Phenylketonuria (PKU) Medications – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of PKU Medications
- C. Prior Authorization of PKU Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of PKU Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

13. Action Item – Annual Review of Ileal Bile Acid Transporter (IBAT) Inhibitors – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of IBAT Inhibitors
- C. Prior Authorization of IBAT Inhibitors
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of IBAT Inhibitors

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

14. Annual Review of Lung Cancer Medications and 30-Day Notice to Prior Authorize Augtyro™ (Repotrectinib) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Lung Cancer Medications
- C. Prior Authorization of Lung Cancer Medications
- D. Market News and Updates
- E. Augtyro™ (Repotrectinib) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Lung Cancer Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

15. Annual Review of Anti-Diabetic Medications and 30-Day Notice to Prior Authorize Inpefa® (Sotagliflozin), Glipizide 2.5mg Tablet, Lantidra™ (Donislecel-jujn), Metformin 625mg Tablet, Zituvio™ (Sitagliptin), and Zituvimet™ (Sitagliptin/Metformin) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Diabetic Medications
- C. Prior Authorization of Anti-Diabetic Medications
- D. Market News and Updates
- E. Product Summaries

- F. College of Pharmacy Recommendations
- G. Utilization Details of Anti-Diabetic Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

16. Annual Review of Age-Related Macular Degeneration (AMD) Medications and 30-Day Notice to Prior Authorize Izervay™ (Avacincaptad Pegol) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of AMD Medications
- C. Prior Authorization of AMD Medications
- D. Market News and Updates
- E. Izervay™ (Avacincaptad Pegol) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of AMD Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

17. Annual Review of Anti-Ulcer Medications and 30-Day Notice to Prior Authorize Prevpak® (Lansoprazole/Amoxicillin/Clarithromycin), Voquenza® (Vonoprazan), Voquenza® Dual Pak® (Vonoprazan/Amoxicillin), Voquenza® Triple Pak® (Vonoprazan/Amoxicillin/Clarithromycin) – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Ulcer Medications
- C. Prior Authorization of Anti-Ulcer Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anti-Ulcer Medications

Items to be presented by Dr. Morgan, Dr. Muchmore, Chairman:

18. Annual Review of Systemic Antifungal Medications and 30-Day Notice to Prior Authorize Rezzayo™ (Rezafungin) – See Appendix P

- A. Current Prior Authorization Criteria
- B. Utilization of Systemic Antifungal Medications
- C. Prior Authorization of Systemic Antifungal Medications
- D. Market News and Updates
- E. Rezzayo™ (Rezafungin) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Systemic Antifungal Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

19. Annual Review of Filspari™ (Sparsentan) – See Appendix Q

- A. Current Prior Authorization Criteria
- B. Utilization of Filspari™ (Sparsentan)
- C. Prior Authorization of Filspari™ (Sparsentan)
- D. Market News and Updates

- E. College of Pharmacy Recommendations
- F. Utilization Details of Filspari™ (Sparsentan)

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

20. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix R

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

21. Future Business* (Upcoming Product and Class Reviews)

No DUR Board meeting scheduled for May 2024.

- A. Amyotrophic Lateral Sclerosis (ALS) Medications
- B. Annual Review of the SoonerCare Pharmacy Benefit
- C. Atypical Antipsychotic Medications
- D. Various Special Formulations

*Future product and class reviews subject to change.

22. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.